HARNESSING THE EVOLUTIONARY POWER OF

T CELLS TO FIGHT SOLID TUMORS

HARNESSING THE EVOLUTIONARY POWER OF T CELLS TO FIGHT SOLID TUMORS

WHO WE ARE

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies.

ascxzsad

TWO PROPRIETARY PLATFORMS

E-ALPHA®

Leveraging high-throughput
screening to develop cancer-
specific antibodies.

Our pipeline highlights the unlimited potential of the ARTEMIS and E-ALPHA platforms to transform the treatment of cancer.

CANCER INDICATION

  • DISCOVERY
  • PRECLINICAL
  • PHASE I/II
  • PHASE III

The EUREKA THERAPEUTICS® approach to fighting solid tumors is to develop multiple potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging our cutting-edge technology platforms.

NEWS UPDATE

CAREERS

At Eureka, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences.

Alexa Willson

CFO

Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.

Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.

Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.